BNLFL said:
I'm curious what the doctors have said about the diarrhea issues?
I spoke with my doctor and informed him that I needed to reduce my GLP1 dosage due to diarrhea and general gastrointestinal issues. He stated that while diarrhea itself likely would not cause AF, a sudden drop in blood pressure could.
I had a look on gemini AI and the answer was:
The relationship between GLP-1 receptor agonists (such as semaglutide) or dual GLP-1/GIP agonists (such as tirzepatide ) and atrial fibrillation is a subject of in-depth study. Clinical research highlights that the correlation is generally inverse : the use of these drugs is associated with a reduction in the risk of developing atrial fibrillation and a lower incidence of recurrence, although there are important nuances to consider.
The Protective Effect (What Large Studies Show)[archived internal link]
Clinical data indicates that GLP-1 agonists exert a protective effect on heart rhythm through two pathways:
1. Indirect Risk Reduction (Weight Loss and Metabolism)[archived internal link]
Obesity and insulin resistance cause significant inflammatory stress on the heart, promoting the accumulation of fat around the myocardium (epicardial adipose tissue). This fat releases inflammatory molecules that alter the electrical activity of the atria, leading to fibrosis and atrial fibrillation.
The weight loss and metabolic improvement induced by molecules like tirzepatide remove this "fertile ground," reducing the heart's workload and negative remodeling of the atria.
2. Direct Risk Reduction (Independent of Weight)[archived internal link]
Clinical studies show that $\text{GLP-1}$ agonists reduce the incidence of new-onset atrial fibrillation and the need for procedures such as cardioversions or ablations, with benefits observed even in patients who did not experience significant weight loss . This suggests a direct anti-inflammatory and electrical stabilizing effect on heart cells.
Potential Triggers (The Risks)[archived internal link]
Despite the long-term protective effect, there are temporary dynamics related to the use of these drugs that, in predisposed individuals, can act as a "trigger" for an arrhythmic episode:
1. Increase in Resting Heart Rate[archived internal link]
It is well-documented that GLP-1 agonists cause a mild increase in resting heart rate (averaging 2-5 beats per minute) due to direct stimulation of specific receptors in the heart's sinus node. Although this increase is generally harmless, in a vulnerable or unstable heart, an elevation in baseline heart rate can sometimes trigger or facilitate an arrhythmic crisis.
2. Dehydration and Electrolyte Imbalances[archived internal link]
Tirzepatide and other agonists drastically reduce appetite and, sometimes, the sensation of thirst. If gastrointestinal side effects (such as nausea or vomiting) occur, or if one simply forgets to drink, the risk of dehydration increases.
A reduction in body fluids causes a drop in blood pressure, which the body compensates for by releasing adrenaline.
This adrenergic spike, combined with the potential loss of vital minerals (such as potassium and magnesium) through sweat or reduced dietary intake, constitutes a strong trigger for atrial fibrillation.
[archived internal link]
